[Preliminary studies on in vitro and in vivo thrombolytic activities of thrombolytic enzyme from an induced Bacillus subtilis strain].
To separate and purify a novel thrombolytic enzyme (FSC2-13) from culture media of an induced Bacillus subtilis strain and to study its in vitro and in vivo thrombolytic activities. Employed fibrin plate method, pyrogenation (heating up) fibrin plate method and SDS-PAGE were used respectively to study FSC2-13 hydrolyzing fibrin and fibrinogen in vitro. Investigations were made on its in vivo pharmacodynamics using rat thrombogenesis inhibition model after it was administrated by intestinal route. FSC2-13 could hydrolyze fibrin and fibrinogen in vitro and had hydrolysis sites on three peptide chains of fibrinogen. FSC2-13 could significantly inhibit the formation of rat venous thrombus after being administrated by intestinal route. Thrombogenesis inhibition rate was 68%. Activated partial thromboplastin time increased by 51%, fibrinogen content decreased by 49%, fibrin degradation product (FDP) content also increased obviously, but the plasminogen content did not change obviously. FSC2-13 possessed in vitro and in vivo thrombolytic activities in a special way. There seem to be prospects for researches to develop it into a new generation of oral thrombolytic drug.